Tirzepatide and semaglutide are both incretin-receptor agonists approved for type 2 diabetes and obesity, but they target different receptor combinations. Tirzepatide is a dual GLP-1 / GIP receptor agonist. Semaglutide is GLP-1-only. In the SURMOUNT-5 head-to-head obesity trial, tirzepatide produced about 47% greater weight loss than semaglutide at peak doses (~20.2% vs ~13.7% mean body-weight reduction at 72 weeks). In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced greater HbA1c reductions at every comparable dose. Side-effect profiles are similar, both GI-dominant, with tirzepatide showing slightly higher rates of nausea and vomiting in some trials.
The short version
Semaglutide and tirzepatide are the two dominant GLP-1-class compounds in the obesity and type 2 diabetes market. They share a clinical lineage (both injectable weekly incretin-receptor agonists), they share an FDA-approval lineage (both went through the obesity-indication pathway after diabetes approval), and they share most of the side-effect shape (GI-dominant during titration).
The mechanism is where they part ways. Semaglutide is a GLP-1-receptor agonist alone. Tirzepatide is a dual agonist at GLP-1 and GIP. The dual activation appears to produce a meaningful difference in outcomes - larger weight loss in obesity trials and larger HbA1c reductions in diabetes trials, in every published head-to-head comparison so far.
Mechanism
Semaglutide binds the GLP-1 receptor with high affinity. GLP-1 receptor activation increases glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite via central nervous system pathways. The compound is a 31-amino-acid peptide modified from native GLP-1 to resist DPP-4 degradation and to bind albumin for extended circulation. Plasma half-life is approximately 7 days, which supports once-weekly dosing.
Tirzepatide binds two receptors. Like semaglutide, it activates GLP-1. Unlike semaglutide, it also activates GIP (glucose-dependent insulinotropic polypeptide), the other major incretin hormone. GIP-receptor activation in this context appears to amplify the insulinotropic effect, contribute additional weight-loss signaling, and possibly modulate the GI side-effect profile in ways the research community is still characterizing. Plasma half-life is approximately 5 days, also supporting once-weekly dosing.
The dual-agonist hypothesis - that activating both incretin pathways produces effects neither receptor alone can - was the principal scientific motivation for Eli Lilly's tirzepatide program. SURPASS-2 and SURMOUNT-5 are the trials that tested whether the hypothesis translated into outcomes. The answer in both cases was yes.
Head-to-head weight loss: SURMOUNT-5
SURMOUNT-5 (Aronne et al., NEJM 2024) is the trial buyers and clinicians cite most often when comparing the two compounds for weight loss. 751 adults with obesity and at least one weight-related complication (but not type 2 diabetes) were randomized to tirzepatide 10 or 15 mg weekly versus semaglutide 2.4 mg weekly for 72 weeks.
Mean body-weight reduction at 72 weeks:
| Arm | Mean weight reduction |
|---|---|
| Tirzepatide (max tolerated 10 or 15 mg) | 20.2% |
| Semaglutide 2.4 mg | 13.7% |
The 6.5-percentage-point absolute difference works out to about a 47% relative advantage for tirzepatide. Categorical outcomes pointed in the same direction: 31.6% of tirzepatide patients reached ≥25% body-weight reduction, versus 16.1% on semaglutide.
This is the first and so far only head-to-head trial of the two compounds in obesity. It does not settle every clinical question (the trial enrolled adults with obesity but not type 2 diabetes, did not stratify by baseline BMI in detail, and used a single semaglutide dose), but it is the strongest direct comparison available.
Head-to-head diabetes: SURPASS-2
For type 2 diabetes, the relevant head-to-head is SURPASS-2 (Frias et al., NEJM 2021). 1,879 adults with T2D inadequately controlled on metformin were randomized to tirzepatide 5, 10, or 15 mg weekly versus semaglutide 1 mg weekly for 40 weeks.
HbA1c reduction at 40 weeks:
| Arm | Mean HbA1c reduction |
|---|---|
| Tirzepatide 5 mg | -2.01 percentage points |
| Tirzepatide 10 mg | -2.24 |
| Tirzepatide 15 mg | -2.30 |
| Semaglutide 1 mg | -1.86 |
Weight reduction at 40 weeks:
| Arm | Mean weight reduction |
|---|---|
| Tirzepatide 5 mg | 7.6 kg |
| Tirzepatide 10 mg | 9.3 kg |
| Tirzepatide 15 mg | 11.2 kg |
| Semaglutide 1 mg | 5.7 kg |
SURPASS-2 used semaglutide 1 mg, which is below Wegovy's peak obesity dose of 2.4 mg. That matters: SURPASS-2 is the strongest comparison at semaglutide's typical T2D dose, not at semaglutide's peak weight-loss dose. SURMOUNT-5 is the trial that compared the two compounds when both were dosed for weight loss.
Tolerability and side effects
Both compounds carry the same general side-effect shape: GI-dominant, concentrated during titration, declining over time.
Nausea rates in SURPASS-2 at the 40-week mark:
| Arm | Nausea incidence |
|---|---|
| Tirzepatide 5 mg | 17% |
| Tirzepatide 10 mg | 19% |
| Tirzepatide 15 mg | 22% |
| Semaglutide 1 mg | 18% |
Diarrhea, vomiting, and decreased appetite tracked similarly. Discontinuation rates due to adverse events ranged 5-9% across all arms in both trials. The compounds appear interchangeable on tolerability shape; the absolute rates run modestly higher on tirzepatide at peak dose, consistent with the larger pharmacological effect.
Both compounds carry FDA boxed warnings for medullary thyroid carcinoma (MTC), based on rodent C-cell tumor findings. No causal MTC signal has been established in humans for either compound, and the warning text is identical between the two product labels. Both are contraindicated for patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Pancreatitis signals remain a background concern for the entire GLP-1 class. Trial-level evidence has not established a consistent excess pancreatitis risk for either compound versus comparator, but real-world surveillance data continues to be reviewed.
Brand-name disambiguation
The brand-name landscape is one of the most-searched questions on the topic and worth stating cleanly.
Tirzepatide is one molecule, two brand names:
- Mounjaro - FDA-approved 2022 for type 2 diabetes
- Zepbound - FDA-approved 2023 for obesity
Semaglutide is one molecule, three brand names:
- Ozempic - FDA-approved 2017 for type 2 diabetes (weekly subcutaneous)
- Wegovy - FDA-approved 2021 for obesity (weekly subcutaneous, higher dose ladder)
- Rybelsus - FDA-approved 2019 for type 2 diabetes (daily oral tablet)
Within each manufacturer's lineup, the brands differ in labeled indication, formulation, or titration ladder. The molecule is the same. Mounjaro and Zepbound contain the same tirzepatide. Ozempic and Wegovy contain the same semaglutide (Rybelsus uses an oral absorption enhancer).
This matters for buyer-facing comparisons. "Ozempic vs Mounjaro" is the same question as "semaglutide vs tirzepatide" with two brand-name labels swapped in. "Wegovy vs Zepbound" is the same question at peak obesity doses. We use the molecule names throughout because the research evidence is at the molecule level, not the brand level.
Pricing and compounded channel
US list prices as of mid-2026 are broadly similar between the two compounds:
- Mounjaro and Zepbound list near $1,000-1,100 per month at retail without insurance.
- Ozempic and Wegovy list near $1,000-1,350 per month at retail without insurance.
Both manufacturers run patient-assistance programs and savings cards that bring covered out-of-pocket costs into the $25-150 per month range for some patients. Coverage by commercial and Medicare Advantage plans varies widely and is the dominant cost variable for most US buyers.
The compounded-pharmacy channel is the dynamic part of the pricing picture. Through 2023-2024, FDA shortage-status declarations allowed 503A compounding pharmacies to prepare semaglutide and tirzepatide formulations at much lower prices ($200-400 per month). The tirzepatide shortage was removed in late 2024 and FDA enforcement discretion on compounded tirzepatide ended in March 2025. The semaglutide shortage closed similarly. The market consequence is documented in our 503A and the PCAC compounding-restriction article and our compounded semaglutide 2026 status read.
The research-peptide channel (vendors selling research-grade material with COAs) is a different market entirely, not labeled for human use, priced at $20-100 per milligram for either compound, and the subject of our vendor audit work.
What the trial data does NOT settle
Three honest limitations on the head-to-head comparison.
SURMOUNT-5 used one semaglutide dose. The trial randomized against semaglutide 2.4 mg weekly, which is the FDA-approved Wegovy peak dose. Some clinicians use semaglutide at higher off-label doses in tolerant patients; those doses were not tested. The 47% relative advantage for tirzepatide is at the approved peak comparison, not the maximum-tolerable comparison.
Long-term durability beyond two years is thin for both. Trial durations have run 40 to 72 weeks, with extension data extending to two years for some cohorts. Five and ten-year weight-maintenance evidence does not yet exist for tirzepatide, and is limited for semaglutide. Both compounds appear to produce weight regain on discontinuation, but the comparative regain trajectories are not well-characterized.
Cardiovascular outcomes are stronger for semaglutide right now. Semaglutide has positive CVOT data from the SUSTAIN-6 (T2D) and SELECT (obesity without diabetes) trials, the latter showing a 20% relative reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease. The equivalent tirzepatide CVOT (SURPASS-CVOT) is ongoing and not yet read out as of mid-2026. On the available data, semaglutide has stronger cardiovascular-benefit evidence; tirzepatide has stronger weight-loss and glycemic evidence.
Related reading
- Retatrutide vs Tirzepatide: a research comparison - the next-generation triple agonist in Eli Lilly's pipeline, with TRIUMPH Phase 3 results.
- Compounded semaglutide in 2026: where the legal channel actually stands - the 503A pharmacy market dynamics.
- 503A and the PCAC: how compounding restrictions closed the legal GLP-1 market - the regulatory backstory on the compounded channel.
- Tirzepatide peptide page - the vendor-audit and COA data for research-grade tirzepatide.
- Semaglutide peptide page - the vendor-audit and COA data for research-grade semaglutide.
- FDA peptide enforcement 2024-2026 - the regulatory timeline that has shaped this market.
Sources
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. 2024.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021;385:503-515.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine. 2021;384:989-1002.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389:2221-2232.
- FDA Drug Approval Package - Mounjaro (tirzepatide). 2022.
- FDA Drug Approval Package - Zepbound (tirzepatide). 2023.
- FDA Drug Approval Package - Ozempic (semaglutide). 2017.
- FDA Drug Approval Package - Wegovy (semaglutide). 2021.
- Eli Lilly product labels - Mounjaro, Zepbound (2024 revisions).
- Novo Nordisk product labels - Ozempic, Wegovy, Rybelsus (2024 revisions).
Frequently asked
What's the main difference between tirzepatide and semaglutide?
Mechanism. Tirzepatide activates two incretin receptors simultaneously, GLP-1 and GIP. Semaglutide activates only GLP-1. The dual-receptor activation in tirzepatide produces larger weight-loss and glycemic effects in head-to-head trials, though both compounds are clinically meaningful by themselves. Side-effect profiles are similar in shape (GI-dominant) but tirzepatide shows modestly higher rates of nausea, vomiting, and diarrhea in some trials.
Which one causes more weight loss?
Tirzepatide, in every head-to-head comparison published so far. The SURMOUNT-5 trial (Aronne et al., NEJM 2024) randomized 751 adults with obesity to tirzepatide 10 or 15 mg weekly versus semaglutide 2.4 mg weekly. At 72 weeks, mean body-weight reduction was 20.2% with tirzepatide versus 13.7% with semaglutide. That is roughly a 47% relative advantage for tirzepatide at peak doses.
Which one lowers blood sugar more?
Tirzepatide. The SURPASS-2 head-to-head diabetes trial (Frias et al., NEJM 2021) compared all three tirzepatide doses (5, 10, 15 mg) against semaglutide 1 mg in adults with type 2 diabetes. HbA1c reductions were greater at every tirzepatide dose, with the 15 mg arm dropping HbA1c by about 2.3 percentage points versus 1.86 for semaglutide 1 mg.
Are the side effects different?
The shape is similar, the rates differ. Both compounds cause GI side effects (nausea, vomiting, diarrhea, constipation) most often during titration. SURPASS-2 showed nausea in about 22% of tirzepatide 15 mg patients versus 18% on semaglutide 1 mg. SURMOUNT-5 showed broadly similar discontinuation rates between arms (about 6-7% from adverse events). Both compounds carry an FDA boxed warning for thyroid C-cell tumors based on rodent data.
What are the brand names?
Tirzepatide is sold by Eli Lilly as Mounjaro (FDA-approved for type 2 diabetes, 2022) and Zepbound (FDA-approved for obesity, 2023). Semaglutide is sold by Novo Nordisk as Ozempic (T2D, 2017), Wegovy (obesity, 2021), and Rybelsus (oral T2D, 2019). Within each manufacturer's lineup, the brands differ in labeled indication, not in the underlying molecule.
Which has a longer half-life?
Semaglutide, slightly. Semaglutide has a half-life of approximately 7 days. Tirzepatide has a half-life of approximately 5 days. Both support once-weekly subcutaneous dosing. The half-life difference is not clinically meaningful for weekly injection but matters for missed-dose tolerance and for any research protocol calculating steady-state concentrations.
Can I switch from semaglutide to tirzepatide (or vice versa)?
That is a clinical decision for a prescribing clinician. Trial-level evidence does not establish a single "right" switching protocol. Common clinical practice when switching from semaglutide to tirzepatide is to start at tirzepatide 5 mg (skipping the 2.5 mg titration starter dose) if the patient has been stable on semaglutide 1 mg or higher, but this varies by clinician and patient profile. Research-protocol contexts are different and not human-use guidance.
Is one cheaper than the other?
List prices in the US are roughly similar but trending. As of mid-2026, Mounjaro and Zepbound list near $1,000-1,100 per month at retail. Ozempic and Wegovy list near $1,000-1,350 per month. Compounded semaglutide and tirzepatide (503A pharmacy) priced at $200-400 per month through 2024, but the FDA shortage-discretion window has closed for tirzepatide and the compounded channel has contracted for semaglutide. Research-grade material from peptide vendors prices lower but is not labeled for human use.
Which one causes less muscle loss?
Neither one has been studied with muscle loss as a primary endpoint, and the available evidence does not cleanly separate the two on lean-mass preservation. SURMOUNT-1 (tirzepatide) and STEP-1 (semaglutide) both report DEXA substudies showing that roughly 25-40% of total weight loss came from lean body mass, which is consistent with non-pharmacological weight loss of similar magnitude. The clinically actionable inference, supported across the GLP-1 class, is that resistance training and adequate protein intake during weight loss are protective against lean-mass loss regardless of which compound is used. We covered this in more detail in our [muscle loss on GLP-1 article](/articles/muscle-loss-on-glp1).